Drug Re-Purposing - Can Anti-Allergy Drugs also be Used to Treat Cancer?
Moschou Georgia and Topham H. Caroline.
Journal Title:Acta Scientific Microbiology
Medulloblastoma (MB) constitutes the commonest malignant childhood brain cancer, and it is the leading cause of death in infants under 1 year. Treatment approaches, such as surgery, radiation, and chemotherapy, have significantly enhanced in patients’ clinical outcome with approximately more than 60% of 5-year survival. Nevertheless, the majority of cancer patients deal with long-term side effects. So, it is important to develop novel therapeutics with lower toxicity and increased efficacy. The present project was conducted to examine if the anti-allergy drugs can inhibit the cancer growth. More specifically, eight anti-allergy compounds, designed by the chemists at University of Central Lancashire (UCLAN), were evaluated for their anti-cancer activity against medulloblastoma. The effect of each testing drug was tested with the use of MTT assay after three days of incubation on medulloblastoma ONS76 cell line. From the extraction of the results of these anti-allergy compounds, it was found that only three of them (CL1-45-1, CL1-56-1, CL1-57-1) were more active, as they significantly inhibited the cancer growth. But, the CL1-42-1 compound displayed the greatest anti-cancer activity against the medulloblastoma ONS76 cells with IC50 = >10 μΜ (IC50 = 0 μΜ). This leads to the conclusion for further investigation of the anti-allergy compounds in order to consider them as potential anti-cancer agents